| 15.27 1.87 (13.96%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.8 |
1-year : | 21.96 |
| Resists | First : | 16.1 |
Second : | 18.8 |
| Pivot price | 14.25 |
|||
| Supports | First : | 13.33 |
Second : | 11.63 |
| MAs | MA(5) : | 13.98 |
MA(20) : | 14.39 |
| MA(100) : | 10.3 |
MA(250) : | 10.09 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.6  |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 18.6 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 16.1 | Low : | 4.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NEO ] has closed below upper band by 0.9%. Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.11 - 16.18 | 16.18 - 16.25 |
| Low: | 14.55 - 14.61 | 14.61 - 14.69 |
| Close: | 15.15 - 15.25 | 15.25 - 15.37 |
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Wed, 29 Jul 2026
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $19.72, Implies 47% Upside - TradingView
Wed, 29 Jul 2026
Why NeoGenomics (NEO) Stock Is Up Today - TradingView
Wed, 29 Jul 2026
NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings - MarketBeat
Wed, 29 Jul 2026
Needham raises Neogenomics stock price target on strong Q2 results - Investing.com
Wed, 29 Jul 2026
NeoGenomics Reports Second Quarter 2026 Results - BioSpace
Wed, 29 Jul 2026
Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 130 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 108.4 (%) |
| Shares Short | 13,760 (K) |
| Shares Short P.Month | 8,450 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.38 |
| Profit Margin | -13.4 % |
| Operating Margin | -9.4 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -11.6 % |
| Qtrly Rev. Growth | 11.1 % |
| Gross Profit (p.s.) | 2.46 |
| Sales Per Share | 5.72 |
| EBITDA (p.s.) | 0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | 33 (M) |
| PE Ratio | -19.84 |
| PEG Ratio | 2 |
| Price to Book value | 2.38 |
| Price to Sales | 2.66 |
| Price to Cash Flow | 88.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|